Hemophilia Clinical Trial
— ExigencyOfficial title:
An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their Families
NCT number | NCT04723680 |
Other study ID # | v3Nov2020 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 13, 2020 |
Est. completion date | February 28, 2023 |
Verified date | February 2023 |
Source | Haemnet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study programme aims to examine the real-world experience and impact of gene therapy in a diverse community of people and families affected by haemophilia who have been or will be exposed to gene therapy.
Status | Completed |
Enrollment | 69 |
Est. completion date | February 28, 2023 |
Est. primary completion date | February 28, 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 16 Years to 100 Years |
Eligibility | Inclusion Criteria: - People with haemophilia A or B who consented to and have undergone gene therapy in the early dose-finding studies and a member of their family - People with haemophilia A or B who consented to a gene therapy trial following the results of the early studies and a member of their family - People with haemophilia A or B who consented to a gene therapy trial but who withdrew, were withdrawn from, or were ineligible for the study, and a member of their family - People with haemophilia A or B who are definitely not interested in or unaware of gene therapy and a member of their family - People with haemophilia A or B who are interested in but have not been offered gene therapy - Those who have given written consent to be in the study - All participants will be =16 years. Exclusion Criteria: - Participants will be excluded if they do not speak English (for the interviews) or do not consent to be in the study. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Oxford University Hospitals NHS Foundation Trust | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
Haemnet | UniQure Biopharma B.V. |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | patient expectations | To explore the expectations that patients, and families in the UK have of gene therapy and its position in contemporary and future haemophilia management | Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach | |
Secondary | Lived experience | To understand the lived experience of people who have undergone gene therapy | Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach | |
Secondary | Impact of gene therapy | To understand the as yet "unseen" impact of gene therapy on the extended family | Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach | |
Secondary | Impact of ineligibility | To understand the impact of ineligibility for gene therapy trials | Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach | |
Secondary | Impact of withdrawal | To understand the impact of withdrawal from gene therapy on individuals and their ongoing attitude to their haemophilia care | Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach | |
Secondary | Why not interested | To understand why some patients and families opt not to participate in gene therapy trials as a treatment option | Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05617209 -
In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
|
||
Completed |
NCT05039008 -
Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy
|
N/A | |
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Terminated |
NCT02586012 -
Weight-based Dosing in Hemophilia A
|
Phase 2 | |
Completed |
NCT02546622 -
ATHN 2: Factor Switching Study
|
||
Unknown status |
NCT02165592 -
Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia
|
N/A | |
Completed |
NCT02165462 -
Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy
|
N/A | |
Unknown status |
NCT02433782 -
Myofascial Therapy in Patients With Hemophilic Arthropathy
|
N/A | |
Completed |
NCT01232634 -
Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles
|
Phase 2 | |
Completed |
NCT05104164 -
Self-myofascial Release in Hemophilic Ankle Arthropathy
|
N/A | |
Terminated |
NCT01191372 -
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
|
Phase 1 | |
Completed |
NCT05173129 -
Posture Analysis for Patients With Haemophilia
|
N/A | |
Completed |
NCT03818529 -
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
|
||
Withdrawn |
NCT03996486 -
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
|
Phase 1 | |
Completed |
NCT03842605 -
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
|
N/A | |
Completed |
NCT01708564 -
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
|
Phase 1 | |
Completed |
NCT05549843 -
Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle
|
N/A | |
Recruiting |
NCT06010953 -
SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT05027230 -
A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06014320 -
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
|